SCHEMBL4138347

SCHEMBL4138347

CCOC(=O)Cc1ccc(NC2=NC(=O)C(=Cc3ccc4ccccc4c3)S2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 7/20 0.46
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
HPGD P15428 4/20 0.43
MITF O75030 3/20 0.43
MAPT P10636 3/20 0.43
ALDH1A1 P00352 3/20 0.43
RAB9A P51151 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 1/20 0.42
DHODH Q02127 1/20 0.40
PTPN1 P18031 1/20 0.39
ACP1 P24666 1/20 0.39
CISD1 Q9NZ45 1/20 0.39
CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4138341 1.00 ALOX5 (0.46) ALOX5MEN1KMT2AHPGDMITF
SCHEMBL4140263 0.87 ALOX5 (0.47) ALOX5MEN1KMT2ARAB9APTPN1
SCHEMBL4140267 0.87 ALOX5 (0.47) ALOX5MEN1KMT2ARAB9APTPN1
SCHEMBL4143423 0.82 ALOX5 (0.47) ALOX5MEN1KMT2AHPGDMITF
SCHEMBL4143427 0.82 ALOX5 (0.47) ALOX5MEN1KMT2AHPGDMITF
SCHEMBL4635040 0.82 FFAR1 (0.49) ALOX5MEN1KMT2AHPGDRAB9A
SCHEMBL4635037 0.82 FFAR1 (0.49) ALOX5MEN1KMT2AHPGDRAB9A
SCHEMBL4139742 0.81 EGFR (0.45) ALOX5MEN1KMT2AHPGDMAPT
SCHEMBL4122971 0.81 EGFR (0.45) ALOX5MEN1KMT2AHPGDMAPT
Propionic Acid SCHEMBL4295430 0.81 ALOX5 (0.45) ALOX5MEN1KMT2ARAB9APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALOX5 3505/4885MEN1 4075/4885KMT2A 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.